slides · global inventory
Callout
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 41,369
Current window 33,841-33,870
Pages 1,379
Rows per page 30
Component
33,841-33,870 of 41,369
09
The slide uses a 'Wayne Enterprises' t-shirt as a subtle nod to the 'enthusiast' theme.eBay | Results Presentation Deck | 35 slides · eBay
Conference presentation Investor relations Loop · Logic Chain1 hit
09
Includes a process timeline and specific investment breakdown for capacity expansion.Eos Energy | Results Presentation Deck | 19 slides · Eos Energy Enterprises
Conference presentation Investor relations Beat · Satisfaction1 hit
19
The slide uses a green-themed sidebar for upcoming events and a structured table for KPI performance.Eos Energy | Results Presentation Deck | 19 slides · Eos Energy Enterprises
Conference presentation Investor relations Beat · Action1 hit
06
Includes specific financial breakdown of deal value and R&D funding obligations.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Solution1 hit
10
Uses a visual comparison framework to illustrate the 'Goldilocks' problem in drug development.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Problem1 hit
11
The diagram uses a hub-and-spoke model to show how various scientific disciplines feed into the central 'Drug Products' core.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
12
The slide uses a hub-and-spoke visual metaphor to explain the shared signaling mechanism of the γC receptor family.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
15
The slide uses a visual mechanism to show how different inhibitors interact with cell signaling pathways.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
17
The slide uses a four-column structure to explain the target, the molecule, the preclinical results, and the clinical results.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
18
The slide uses a column-based layout to compare four distinct disease indications.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Market Size1 hit
19
The slide uses Western blot data to visually demonstrate the efficacy of EQ101 compared to a standard JAK inhibitor.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
20
Includes before/after clinical photos and a comparative table against Mogamulizumab.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Traction1 hit
22
The slide uses a circular process diagram to show the feedback loop of immune cells and cytokines attacking the hair follicle.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
23
Includes visual longitudinal study (Day 0, 14, 21) and a bar chart comparing efficacy against PBS and Ruxolitinib.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
25
Includes a specific callout for a Blackbox warning on existing competitors.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
26
Includes a timeline-style process diagram for the study phases.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
28
The slide uses a four-column layout to explain the target, the molecule structure, the mechanism of action, and the current clinical status.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
29
Equillium | Investor Presentation Deck | 39 slidesEquillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
30
Includes a biological process diagram and a gene expression heatmap.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
31
The slide uses a biological pathway diagram and a bar chart to demonstrate efficacy.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
32
The slide uses a process-like diagram to show treatment approaches and highlights the specific mechanism of action (IL-15/IL-21 inhibition) as a superior strategy.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
37
The slide provides a snapshot of the company's financial health as of late 2023.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
38
The slide uses a grouped list format to present clinical trial milestones.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
08
The slide uses a biological process diagram to map drug assets to specific protein targets.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needsLoop · Logic Chain1 hit
13
The slide combines a biological pathway diagram with a clinical trial summary table to demonstrate proof of concept.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needs1 hit
15
The slide highlights the poor efficacy of current SOC and suggests binimetinib as a superior alternative.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needsLoop · Cost Of Inaction1 hit
18
The slide uses a swimmer plot to visualize individual patient treatment duration and response status.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical dataLoop · Cost Of Inaction1 hit
19
The slide uses a summary calculation (13/39 = 33.3% ORR) to aggregate results across two different clinical phases.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical dataLoop · Cost Of Inaction1 hit
21
The diagram uses a flow-chart structure to categorize patient outcomes (off treatment vs on treatment) and further breaks down the 'on treatment' group into SDs and PRs with specific progression delay metrics.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
36
The diagram shows the EGFR signaling pathway and the inhibitory effect of ERAS-801.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit